Member Info for Diversified

That would make sense Peter.

I have contacted walbrookpr to ask if they intend to take part in any IR as it’s frustrating to see other diagnostic companies shouting from the rooftops and if anything over ramping their prospects yet the single piece of IR ODX participated in resulted in a speeding ticket.

I feel very comfortable with my position at this level and the market makers are prepared to take 200k as a single trade around 53p which shows the level of support.

When the market receives any notion of a design freeze it has become difficult to buy the stock and I believe it is reasonable to assume that the market will begin to price in a design freeze in the 70’s before the event occurs with only 13 working days left. Favorable tweets at the end of the trading day today by Abingdon health further teases the market of what is to come, but in itself shows the level of confidence they have in the likelihood of the product coming to market.

Saliva or swab sample?

So any one of the three options, I.e. what AVCT are proposing.

I think this has been missed by the market and that cheaper tests for alternative markets (15) are soon to hit the tape and add to the considerable opportunity that ODX has taken a strategic decision to fully commit to.

I am not trying to ramp, I’m just looking to see if my research has taken me along the right lines as we have had limited to no Investor relations from the company to help map the companies new business model!

From the most recent RNS am I right to assume:

‘ a lateral flow antigen test product that determines the concentration of COVID-19 (SARS-CoV-2) antigens in a human blood, saliva, or swab extract sample also used to identify an individual with an infection’

That Mologic in partnership with ODX are developing a lateral flow antigen test for saliva just like AVCT?

Decent volume, must be a delayed trade as buys far exceed reported buys.

JORC opens up feasibility study and detail on reported 2 year mine construction to 10k tones per annum.

I have no doubt that the trade war is to escalate between China and America and I think the link below tells us how things are developing strategically but it’s yet to hit the mainstream media.

Funding shouldn’t be difficult given quality of the license and relative low development cost.

We all know in combination with the JORC and potential trade war, attention is imminent.

Was please to get a few at 5.75 first thing but now it’s NM again. Anyone else able to buy? I see a trade went through while Iv been trying to buy

That was infuriating, couldn’t buy anything at 6p. Provided a quote but when I accepted it, it kept saying error. Time out.

Was watching the sells going through, it was as if the Mm’s had gone long overnight!

Tomorrow is going to be another good day.

Provides a quote but won’t complete transaction

It says in the RNS that they are looking to raise capital for expansion in this high growth sector.

They couldn’t raise cash on aim without significant dilution.

Loan conversion agreed at 5p. This is normally converted at a 30/40% min discount to market price. I.e. the new price on HKex

You can’t buy shares for toffee, not even at 5.7p.

Sector average P.E. Would give this a market cap of 53m or about 12p.

Given the high growth and looking at peers, 24p realistic.

Pwc has audited the company, strong confidence in books.

The directors have significant skin in game, no shares for sale other than PI profit taking, but the bigger picture will reveal itself.

You don’t make two applications unless your confident the second is likely to be accepted.

Congrats to all LTH here as to persevere with this one must of taken patience.

I am getting frustrated at not being able to buy, AGAIN

Forget HK listing, the fundamentals have never been fairly priced with this company. This is the most obvious bagger I have seen in months.

I have run the numbers and if anyone else takes the time to do a bit of research and do the same you will make good money.

You just can’t buy any. Same as Friday, these arguably present value all the way up to 10p

Lanstead last facilitated the fundraise when they knew of a strong pipeline of news, the same applies now.

I have no doubt the IMM will play a part in the fight against COVID and that lanstead is of the same opinion. This will be the next update imo and when you look at SNG current market cap, the upside is clear for all to see.

Patience will be rewarded from these levels

Convertible loans are normally done at a 30/40% discount to the actual share price. This provides the lender with assurances that it would be able to convert it’s borrowings on the free market plus interest of a minimum 12% as per the RNS or more in the event of a conversion to equity.

All this leads to the assumed share price of between 8 and 11p depending on the level of funds raised as part of the Hong Kong listing.

It’s going to be an exciting week.

Thank you, I’ll start following him.

Expect migration from Aim to the Hong Kong exchange before the expiration of the AGM resolutions on the 15 July 2020.

We also know they will provide a minimum 10 working days notice to allow shareholders to make a decision on if they should sell on the aim exchange or arrange a transfer with their broker for Hong Kong dealing.

For this to happen within the required guidelines we should expect an update during the month of June, very exciting times.

Some great info their guys. I will do a deep dive into the company further this weekend. Has anyone had any comms with the company?

Many articles are referring to governments worldwide opening their fiscal packages to green energy projects as they can be highly labour dependent which will help reduce unemployment. Another reason for my initial investment yesterday.

When a £20m market cap, plenty of scope to buy more at these lower levels imo! I like it!

The current P/E of 3.2 with little debt, a forward order book and contract backlog that has increased by 77.5% to RMB584.9 million (c. GBP67.4 million) from RMB329.6 million (c. GBP37.4 million) for the year ended 31 December 2018. Net profit of 6.8m on its latest final results and a sector average P/E of 7.8 is cheap regardless of the exchange.

Had the company of spent more time on investor relations and communicating progress such as new contract the share price would be considerably higher.

I believe from how they have communicated and continued to pursue the Hong Kong listing that the companies directors who have significant skin in the game would not risk the financial loss if they hadn’t of done their due diligence.

With the market actively finding diamonds in the rough, rises like today leads to increased exposure and when you research the numbers it’s difficult not to take some exposure to what will likely be considerable upside imo.

50,000,000 / 444,447,541 = 11.25p

They are aiming to address the undervaluation of the business with a P/E similar to its peers.

At a sector P/E ratio of 7.8 this would value the company at £53m.

One of the primary reasons for listing on an alternative exchange is to raise money for expansion without causing significant dilution based on current market cap.

So we have a disparity in valuation of £33m based on today’s closing price. Much will depend on how much they are looking to raise by issuing new shares (including the convertibles), but let’s assume they will raise £10m at this point leading to an increase of 50% in shares in circulation.

53,000,000 / 666,671,311 = 7.95p

Now the industry works on a P/E of 10, and given the high growth rate CNEL is presenting, their is scope for considerable upside to the above price. If they raise less, causing less dilution then the same will apply. They are a leader in the sector as per the document Hong Kong listing application.

My target based on speculative but reasonable numbers is 8p. For what it’s worth, if they raise £4m plus convertibles then the price is 9.5p.

All above are approx numbers and speculative but what is clear is that this remains significantly undervalued, and with new money leading to further growth opportunities this is one hell of a company.

My point being these conversions are normally done at a discount to the current share price, in this case the newly listed price. This is why I believe the new listed price will be higher than 5p. Sorry if I was not clear.

Major rerating will continue next week imo.

Yes convertible at 5p

‘ The Loan will be converted automatically into ordinary shares of the Company at a price of HKD0.481 (approximately 5.0 pence) per ordinary share’